Quadrivalent influenza virus split vaccine (Zhifei Longcom)

The quadrivalent influenza virus split vaccine developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. is a biologic vaccine designed for the prevention of influenza virus infection. Utilizing split virion technology, the vaccine contains inactivated virus particles that have been chemically disrupted to eliminate infectivity while preserving key antigenic epitopes, such as hemagglutinin, to induce a robust immune response. This quadrivalent formulation provides broader protection compared to trivalent vaccines by targeting four distinct influenza strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). Clinical development included Phase 3 trials specifically evaluating its safety and immunogenicity in pediatric populations (aged 6-35 months), using both 0.25ml and 0.5ml doses. The vaccine received regulatory approval in China in March 2025, aimed at reducing the burden of seasonal influenza in high-risk groups including children and the elderly.

Other names

quadrivalent influenza virus split vaccine-Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.-influenzaZhifei Longcom quadrivalent influenza vaccinequadrivalent influenza virus split vaccine